



Pitt Therapeutics Advancing in the Drug Development Process



01

PHASE I : SAFETY

Phase I clinical trials are small enrolling less than 30 participants and are designed to find a new dose of the treatment, determine how the treatment should be given, and learn how it affects the body.



PITT STARTUP

ONCR-177, Oncorus' lead candidate, is an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy for the treatment of multiple solid tumor cancers. They are enrolling patients in Phase 1 trials.




PITT STARTUP

Peptilogics, successfully completed their PRE-IND meeting with the FDA for their PLG0206 for the treatment of prosthetic joint infections.



PITT STARTUP

SkinJect is a novel, tip-loaded dissolvable microneedle array being developed for basal cell cancer.



02

PHASE 2 : EFFICACY

If a safe dose is found in Phase I, Phase 2 clinical trials begin enrolling less than 100 participants with the disease or condition. Phase 2 trials study how well the treatment works and looks for side effects.



PITT STARTUP

Forge Biologics, is set to begin Phase I and 2 clinical trials of a gene therapy to treat Krabbe Disease, a rare neurodegenerative disorder that is frequently fatal before age 5.



PITT STARTUP

INB03 is currently in Phase 1 in advanced solid tumors & Phase 2 clinical trial in advanced melanoma patients who are refractory or resistant to CPI and have elevated MDSC in their blood.



PITT STARTUP

Lygenesis, began it's Phase 2a trial of its cell therapy for patients with end stage liver disease (ESLD).



University of Pittsburgh

Innovation Institute
Office of Innovation
and Entrepreneurship